WebNov 17, 2024 · The clinical trial compares standard treatment to an investigational combination therapy for people with high-risk HER2-positive breast cancer. 11/17/2024. ... The CompassHER2 RD study is led by Alliance for Clinical Trials in Oncology, a cooperative research group that designs and conducts clinical trials under the … WebJun 15, 2024 · The CompassHER2 RD trial is evaluating the combination of ado-trastuzumab emtansine (T-DM1; Kadcyla) and tucatinib (Tukysa) vs T-DM1 alone in patients with high-risk HER2-positive breast cancer ...
Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1
WebOct 12, 2024 · This report describes the rationale, purpose and design of A011801 (CompassHER2 RD), an ongoing prospective, multicenter, Phase III randomized trial. Eligible patients in the United States (US) and Canada with high-risk (defined as ER-negative and/or node-positive) HER2-positive (HER2+) residual disease (RD) after a … WebA011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib grants for ice rinks
Breast Cancer Clinical Trials Tower Health
WebLearn more about the EA1181 trial or call Phoenixville Hospital Research Office at 610-983-1811. Alliance-A011801: The CompassHER2 trials (COMprehensive use of Pathologic Response ASSessment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of … WebThe CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-positive Breast Cancer): CompassHER2 Residual Disease (RD), a Double-blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 ... the CompassHER2 RD Trial. Description. T-DM1 and Tucatinib Compared … WebJun 2, 2024 · Further adding complexity, the role of novel anti-HER2 drugs is currently being investigated in this setting within large randomized trials: the DESTINY-Breast05 trial (ClinicalTrials.gov identifier: NCT04622319) is comparing T-DXd with T-DM1 in the postneoadjuvant setting, whereas the CompassHER2-RD trial (ClinicalTrials.gov … grants for ileostomy